PTK7 Expression in Triple-negative Breast Cancer

Ataseven, Beyhan; Angerer, Regina; Kates, Ronald; Gunesch, Angela; Knyazev, Pjotr; Hoegel, Bernhard; Becker, Clemens; Eiermann, Wolfgang; Harbeck, Nadia

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

PTK7 Expression in Triple-negative Breast Cancer

MPS-Authors

/persons/resource/persons78233

Knyazev, Pjotr
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Ataseven, B., Angerer, R., Kates, R., Gunesch, A., Knyazev, P., Hoegel, B., Becker, C., Eiermann, W., & Harbeck, N. (2013). PTK7 Expression in Triple-negative Breast Cancer. ANTICANCER RESEARCH, 33(9), 3759-3763.

引用: https://hdl.handle.net/11858/00-001M-0000-0014-D0F9-9

要旨

Background: Protein tyrosine kinase-7 (PTK7) plays an important role in cancer. Our aim was to evaluate PTK7 in triple-negative breast cancer (TNBC). Materials and Methods: PTK7 Expression was assessed by immunohistochemistry (IHC) in 133 patients with TNBC. Expression levels were correlated with clinicopathological features and survival, taking chemotherapy into account. Results: Positive PTK7 expression was detected in 28.6% of tumors. In the total population, no significant difference was detected in disease-free survival (DFS) or overall survival (OS) related to PTK7 status. However, in patients treated by chemotherapy, patients with PTK7-negative tumors seemed to have better DFS than those with PTK7-positive tumors, particularly for patients treated with only anthracycline-therapy drugs. In patients receiving other chemotherapy regimens, PTK7 status had no significant impact on DFS or OS. Conclusion: Our results support earlier findings that PTK7 may be associated with resistance to anthracycline-based chemotherapy.